Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Cleveland BioLabs (CBLI) Competitors

Cleveland BioLabs logo

CBLI vs. TRVN, ARDS, STAB, EVLO, AMPE, CMRA, CALA, EFTR, HSTO, and PBLA

Should you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and Panbela Therapeutics (PBLA). These companies are all part of the "medical" sector.

Cleveland BioLabs vs. Its Competitors

Trevena (NASDAQ:TRVN) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Trevena has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Trevena presently has a consensus price target of $5.00, suggesting a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Cleveland BioLabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cleveland BioLabs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Trevena's return on equity of 0.00% beat Cleveland BioLabs' return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Cleveland BioLabs N/A -32.84%-31.29%

13.6% of Trevena shares are held by institutional investors. Comparatively, 5.1% of Cleveland BioLabs shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 1.0% of Cleveland BioLabs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Cleveland BioLabs'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Cleveland BioLabs Neutral

Cleveland BioLabs has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.03-$40.29M-$47.040.00
Cleveland BioLabs$260K0.00-$2.40MN/AN/A

Summary

Trevena beats Cleveland BioLabs on 6 of the 9 factors compared between the two stocks.

Get Cleveland BioLabs News Delivered to You Automatically

Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CBLI vs. The Competition

MetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$1.03B$6.13B$10.55B
Dividend YieldN/A4.84%5.72%4.83%
P/E RatioN/A1.3285.7827.06
Price / SalesN/A29.96612.92132.30
Price / CashN/A17.6325.8230.35
Price / BookN/A8.0712.226.58
Net Income-$2.40M-$7.36M$3.33B$276.84M

Cleveland BioLabs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CBLI
Cleveland BioLabs
N/AN/AN/AN/A$3K$260K0.004
TRVN
Trevena
1.4481 of 5 stars
$0.01
flat
$5.00
+41,566.7%
-99.4%$12K$443K0.0040
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat
N/AN/A$11KN/A0.0030Gap Down
STAB
Statera Biopharma
N/A$0.00
flat
N/AN/A$5KN/A0.0020Gap Down
High Trading Volume
EVLO
Evelo Biosciences
N/A$0.00
flat
N/A-33.3%$4KN/A0.00120
AMPE
Ampio Pharmaceuticals
N/A$0.00
flat
N/A+22.7%$3KN/A0.0020
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00M0.002
CALA
Calithera Biosciences
N/A$0.00
flat
N/AN/A$1KN/A0.0060
EFTR
eFFECTOR Therapeutics
0.1491 of 5 stars
$0.00
flat
N/A-83.3%$1KN/A0.0010Upcoming Earnings
HSTO
Histogen
N/A$0.00
flat
N/A-99.9%$1K$19K0.0020
PBLA
Panbela Therapeutics
0.1113 of 5 stars
$0.00
-98.2%
N/A-93.7%$1KN/A0.006Gap Down

Related Companies and Tools


This page (NASDAQ:CBLI) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners